天源集团(06119)发布公告，集团拟开展与中国大健康产业相关的新业务。为促进新业务的发展及推 行，公司已于香港成立一家全资附属公司，并委聘吴宇先生担任该新成立附属公司的总经理。吴先生将 主要负责集团新业务的策略规划、业务发展及营运事宜。 中国大健康产业呈现显著的增长潜力，并受到如"健康中国2030"以及第14个及第15个五年计划等有力的 国家战略所支持。中国政府已将大健康产业的发展提升为国家级战略重点领域，并对包括创新药物、先 进医疗设备及数字医疗等方面提供长期稳定的政策支持。该等政策不仅为促进技术创新，例如将人工智 能与大健康融合及推广数字健康解决方案等，同时亦为人口老化等人口结构变化而设。从而创造大量的 市场机遇，涵盖智慧养老照护、健康管理、预防性医疗及环境健康技术等领域。此外，医疗体系、医疗 保险与药品领域的持续改革正完善产业生态系统，并推动高质量发展。在此背景下，公司看好投资中国 大健康产业的庞大前景，旨在借助政策支持、技术进步及市场需求增长来创造长期价值，并为中国健康 福祉的提升作出贡献。 集团主要从事散货装卸服务、相关配套增值港口服务及油产品的供应及销售。除致力发展现有主要业务 外，公司亦一直致 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 不 會 就 因 本 公 告 全 部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TIAN YUAN GROUP HOLDINGS LIMITED 天源集團控股有限公司 於 本 公 告 日 期，本 集 團 主 要 從 事 散 貨 裝 卸 服 務、相 關 配 套 增 值 港 口 服 務 及 油 產 品 的 供 應 及 銷 售。除 致 力 發 展 現 有 主 要 業 務 外，本 公 司 亦 一 直 致 力 探 索 新 業 務 的可能性與機遇，以實現業務多元化發展、擴充業務組合、擴闊收入來源，並強 化 未 來 盈 利 能 力 與 發 展 潛 力。誠 如 本 公 司 截 至2024年12月31日止年度的年報所 披 露，本 集 團 洞 悉 大 健 康 產 業 帶 來 的 商 機，尤 其 是 有 見 於 中 國 出 現 人 口 老 年 化 的趨勢及對健康管理的需求將日益增加。 （於開曼群島註冊成立的有限公司） （股份代號：6119） 自願性 ...

Core Viewpoint - Qingdao Impulse Health Technology Co., Ltd. is a leading company in the fitness equipment industry, focusing on the research, manufacturing, and brand operation of a full range of fitness equipment, emphasizing functionality, intelligence, and safety [2][3][10]. Group 1: Company Overview - The company was listed on the Shenzhen Stock Exchange in September 2017, becoming the first main board listed company in China's fitness equipment industry [2][3][10]. - Impulse has established a comprehensive product system covering aerobic, strength, and ice and snow categories, with a sales network spanning over 100 countries and regions, providing full-process solutions for various clients including clubs, military, and families [2][3][10]. Group 2: Development and Financial Performance - The company has undergone five strategic phases since its inception in 1991, leading to a global health industry cluster, with a revenue of 1.214 billion yuan in 2024, representing a year-on-year increase of 35.58%, and a net profit of 109 million yuan, up 23.77% year-on-year [3][11]. - In 2024, overseas sales accounted for 78.68% of total sales, showcasing the company's international expansion [4][11]. Group 3: Technological Advancements - Impulse focuses on six core scenarios: commercial fitness, home fitness, outdoor fitness, physical training, health management, and event support, developing smart gyms and indoor skiing simulators as part of its solutions [4][11]. - The company has over 300 valid patents and has participated in setting numerous national and industry standards, including the first national standard for aging-friendly fitness equipment [4][12]. Group 4: Social Responsibility - Impulse is recognized as a training ground for over 3,000 technical experts and 22,000 manufacturing craftsmen, supporting various national and international events and promoting community sports initiatives [5][12]. - The company actively engages in corporate social responsibility, having published the "White Paper on Employee Health Management" in 2020 [5][12].

格隆汇12月17日丨佛慈制药(002644.SZ)在投资者互动平台表示，近年来，公司积极布局大健康产品产 业，先后开发了阿胶糕、袋泡茶、"一支茶"系列汉方茶饮等产品，2024年6月起布局中药养生茶饮，现 已开设佛慈茶馆10家，销售特色药食同源的养生茶饮和膏方产品等。未来公司将持续大力发展大健康产 业，深度融合传统中医药文化与现代健康养生理念，依托"药食同源"产品资源及公司研发优势，开发具 有高附加值和市场潜力的健康食品、特膳食品、功能性饮品及中医药衍生品，推动产业链延伸。 ...

Core Insights - The core viewpoint of the articles highlights the significant role of AI health applications, particularly the upgraded "Ant Fortune" app, in transforming healthcare consultations, especially in the context of pregnancy-related inquiries and enhancing male participation in the process [1][3]. Group 1: AI Health Application Development - The "Ant Fortune" app has over 15 million monthly active users, with approximately 55% from lower-tier cities, showcasing its inclusive nature [1]. - AI applications are increasingly seen as a solution to repetitive inquiries in healthcare, with 70% of offline consultations related to basic lifestyle questions during pregnancy [3]. - The app has attracted 160,000 consultations for its AI avatar of Dr. Duan Tao, a prominent obstetrician, indicating a growing acceptance of AI in healthcare [3]. Group 2: Market Potential and Strategic Moves - The Chinese health industry is projected to exceed 20 trillion RMB by 2025, presenting a significant opportunity for AI health management applications [3]. - Ant Group has upgraded its "Digital Health Division" to a "Health Business Group," emphasizing its commitment to the health sector as a strategic pillar [3]. - The competition in the AI health application space is intensifying, with tech companies vying for data entry points from both hospitals and patients to convert infrequent medical interactions into frequent health consultations [4]. Group 3: Investment and Innovation - The AI medical sector has seen active financing, with companies like Noah AI and SenseTime Medical securing substantial funding, indicating investor confidence in the sector's growth potential [4]. - Despite the funding activity, many AI medical companies have yet to establish clear profit pathways, necessitating the development of competitive and differentiated products to justify their valuations [5]. - Experts emphasize the need for AI tools to evolve beyond simple assistance to become integral to the healthcare system, requiring the accumulation of complex data for improved problem-solving capabilities [5].

Core Insights - The Chinese health industry is entering a significant growth phase, driven by an aging population and increasing acceptance of traditional Chinese medicine [2] - Shouxiangu aims to become a leading brand in organic Chinese medicine and global Lingzhi products, focusing on product quality and consumer trust [3] Company Strategy - Shouxiangu's main products include third-generation wall-breaking Lingzhi spore powder and Dendrobium candidum series, with Lingzhi spore powder accounting for approximately 72% of sales in the first half of 2025 [3] - The company is expanding its market presence outside Zhejiang province, where current sales account for less than 10% [3][4] - Shouxiangu plans to adopt a dual approach for expansion, including learning from successful distributors and forming strategic partnerships with well-known pharmaceutical distribution companies [4] Digital Transformation - The company is leveraging AI technology to enhance production efficiency and product quality, while also utilizing digital marketing to improve customer engagement and conversion rates [4] Industry Challenges - The traditional Chinese medicine sector faces cyclical pressures from high-end consumption contraction and inventory issues, alongside long-term structural challenges [4] - The industry is experiencing a shift in consumer demographics, with younger consumers becoming a significant market segment [4] Marketing and Product Innovation - Shouxiangu is enhancing brand visibility through sponsorships and engaging with new media platforms for broader consumer reach [5] - The company is diversifying its product offerings to appeal to younger consumers, including ready-to-drink products and innovative formats like capsules and oral liquids [5]

Core Insights - Yanjing Beer is expanding into the health industry with its Yanjing Nutrition initiative, focusing on promoting self-developed health products like natto and polypeptides [1][2] - As of the first half of 2025, beer products still account for 92.26% of Yanjing Beer's revenue, amounting to 7.896 billion yuan [1] - The company aims to strengthen its core beer business while diversifying into health products, indicating a strategic shift towards a broader market [1][3] Group 1: Health Product Development - Yanjing Natto, made from fermented soybeans, is highlighted for its high nutritional value, containing essential amino acids, calcium, iron, potassium, and vitamin K2 [2] - The company has established Beijing Yanjing Biotechnology Co., Ltd. in collaboration with the China Food Fermentation Industry Research Institute, focusing on a dual-driven model of "independent research and collaborative development" [2] - Yanjing Beer is committed to providing high-quality health products, emphasizing a focus on fermentation and health [2] Group 2: Financial Performance - For the first nine months of 2025, Yanjing Beer reported a revenue of 13.433 billion yuan, a year-on-year increase of 4.57%, and a net profit of 1.770 billion yuan, up 37.45% [4] - The company is implementing a diversified strategy, combining beer and beverage marketing to enhance its product matrix and market presence [4] Group 3: Product Diversification - Yanjing Beer has launched a beverage line, including the Best Soda series, which aims to complement its beer offerings and expand its commercial portfolio [4] - The health product range includes various items such as natto capsules, polypeptides, organic whole milk powder, probiotics, and fermented liquids, showcasing the company's commitment to health [5]

近日，燕京啤酒在互动平台向投资者表示，燕京营养家是燕京啤酒布局大健康产业的重要市场举措，由 北京燕京中发生物技术有限公司专业运营，作为其线下销售渠道，重点推广燕京纳豆、纳福多肽等自主 研发的健康产品。燕京啤酒总部位于北京市顺义区，公司股票于1997年7月在深交所挂牌上市交易。 2025年1至9月，燕京啤酒实现营收65.45亿元，同比增长8.58%（调整后）；实现归母净利润14.66亿 元，同比下降4.28%（调整后）。2025年上半年，燕京啤酒的啤酒产品实现营收78.96亿元，占营收比重 为92.26%。 ...

聚焦大湾区农交 会 | 云南省展团 携农产好物亮相 大湾区农交会， 等您到来！_南 方+_南方plus 2025大湾区农产 品交易会暨土特 产精品博览会 （简称"大湾区 农交会"）将于 12月12日-14日 在广东·广州广 交会展馆B区盛 大启幕！ 届时，云南省展 团将携云南特色 农产品亮相2025 大湾区农交会， 今天小编就带大 家提前剧透，走 进彩云之南，探 寻这片红土高原 上，都有哪些匠 心好物与舌尖珍 品！ 参展商抢鲜剧透 1 参展企业：云南 十六州云品农业 有限公司 展位号：10.1馆 10T03 企业简介：云南 十六州云品农业 主推产品：冻干 墨红玫瑰 云南高原种植的 墨红玫瑰，因昼 夜温差大（达 15℃）和紫外线 强，花青素含量 为普通玫瑰3 倍。仅取春季 （4-6月）"头水 花"，此时花苞 开放度 30%-35%，精油 与营养物达峰 值。采摘时间只 能在每天早晨的 8点前，这时候 采摘的鲜花保存 更完整，避免日 照蒸发露水与香 气分子。人工分 拣剔除开放度＞ 35%或带虫咬、 霉斑的花朵，12 公斤鲜花仅出产 1公斤成品。冻 干墨红玫瑰富含 花青素、维生素 C等k氧物质。冻 干技术（FD技 术 ...

谭丽霞表示，在这条守护生命健康的道路上，女性特有的敏锐与坚韧正转化为非凡力量。她呼吁："我们欢迎并期待有更多的女性商界领袖参 与共创，以'她智慧'点亮全球生命之光。我们相信，当健康成为人类共同的语言，女性必将是这门语言优秀的译者。" 6月19日，跨国公司领导人青岛峰会"女企业家论坛"在山东青岛举行，海尔集团董事局副主席、执行副总裁，盈康一生董事长谭丽霞在论坛上 表示："中国健康产业正以全球2倍的增速重塑世界格局，在'政策筑基×银发需求×消费升级'的乘数效应下，构建起一个万亿元级的创新试验 场。" 在该峰会女企业家论坛上，谭丽霞发表了题为《共筑健康未来：以女性智慧点亮全球生命之光》的主旨演讲。她以大健康产业为切入点，结 合海尔实践，阐述了在全球产业变局下女性领导力的关键作用。 "在全球化深度融合的今天，健康已成为衡量人类文明进步的核心标尺。"谭丽霞表示，中国不仅是全球医疗健康产业的关键市场，更是孵化 解决方案的策源地。数据显示，2024年中国大健康产业总收入规模已接近9万亿元。作为中国医药健康产业的重要增长极，山东正发挥着创新 示范引领者的角色。 据悉，20年来，盈康一生以科创突破、数智赋能、生态无界、全球引领 ...